[go: up one dir, main page]

HRP20170634T1 - Kristalni oblici od 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida - Google Patents

Kristalni oblici od 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida

Info

Publication number
HRP20170634T1
HRP20170634T1 HRP20170634TT HRP20170634T HRP20170634T1 HR P20170634 T1 HRP20170634 T1 HR P20170634T1 HR P20170634T T HRP20170634T T HR P20170634TT HR P20170634 T HRP20170634 T HR P20170634T HR P20170634 T1 HRP20170634 T1 HR P20170634T1
Authority
HR
Croatia
Prior art keywords
methyl
pyirimidin
fenil
cristalline
ylamino
Prior art date
Application number
HRP20170634TT
Other languages
English (en)
Inventor
Paul W. Manley
Wen-Chung Shieh
Paul Allen Sutton
Piotr H. Karpinski
Raeann Wu
Stéphanie MONNIER
Jörg Brozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170634(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20170634T1 publication Critical patent/HRP20170634T1/hr
Publication of HRP20170634T4 publication Critical patent/HRP20170634T4/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20170634TT 2005-07-20 2017-04-24 Kristalni oblik od 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida HRP20170634T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70140505P 2005-07-20 2005-07-20
US71621405P 2005-09-12 2005-09-12
EP10173956.3A EP2284167B2 (en) 2005-07-20 2006-07-18 Crystalline form of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Publications (2)

Publication Number Publication Date
HRP20170634T1 true HRP20170634T1 (hr) 2017-06-30
HRP20170634T4 HRP20170634T4 (hr) 2020-02-07

Family

ID=37451227

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20120573TT HRP20120573T1 (hr) 2005-07-20 2006-07-18 Kristalni oblici 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino) benzamida
HRP20170634TT HRP20170634T4 (hr) 2005-07-20 2017-04-24 Kristalni oblik od 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20120573TT HRP20120573T1 (hr) 2005-07-20 2006-07-18 Kristalni oblici 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino) benzamida

Country Status (42)

Country Link
US (4) US8343984B2 (hr)
EP (5) EP2535337B1 (hr)
JP (3) JP5289948B2 (hr)
KR (3) KR20130085444A (hr)
CN (2) CN103804356A (hr)
AR (1) AR054846A1 (hr)
AU (3) AU2006276204A1 (hr)
BR (1) BRPI0613615B1 (hr)
CA (1) CA2614334C (hr)
CR (1) CR9657A (hr)
CU (1) CU23916B1 (hr)
CY (2) CY1113076T1 (hr)
DK (2) DK2284167T4 (hr)
EA (2) EA013464B1 (hr)
EC (1) ECSP088119A (hr)
ES (3) ES2386974T3 (hr)
GE (1) GEP20115302B (hr)
GT (1) GT200600315A (hr)
HN (1) HN2008000311A (hr)
HR (2) HRP20120573T1 (hr)
HU (1) HUE031791T2 (hr)
IL (2) IL188189A0 (hr)
JO (1) JO3308B1 (hr)
LT (1) LT2284167T (hr)
MA (1) MA29626B1 (hr)
MX (1) MX2008000899A (hr)
MY (1) MY148554A (hr)
NI (1) NI200800017A (hr)
NO (1) NO341930B1 (hr)
NZ (1) NZ564409A (hr)
PE (1) PE20070214A1 (hr)
PH (1) PH12013501590A1 (hr)
PL (2) PL1912973T3 (hr)
PT (2) PT1912973E (hr)
RS (1) RS55929B2 (hr)
SG (1) SG163620A1 (hr)
SI (2) SI2284167T2 (hr)
SM (1) SMAP200800011A (hr)
TN (1) TNSN08029A1 (hr)
TW (1) TWI406661B (hr)
UA (1) UA94234C2 (hr)
WO (1) WO2007015870A2 (hr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
US20100152198A1 (en) * 2006-04-07 2010-06-17 Manley Paul W Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
PT2240172E (pt) 2007-12-21 2014-05-28 Novartis Ag Combinação de nilotinib e clorambucilo para o tratamento da leucemia linfocítica crónica
EP2305667A3 (en) 2008-07-17 2011-05-11 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
PL2262793T3 (pl) 2008-11-05 2013-01-31 Teva Pharma Formy krystaliczne nilotynibu HCL
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
KR20110132439A (ko) 2009-03-06 2011-12-07 노파르티스 아게 류신 지퍼- 및 스테릴 알파 모티프-함유 키나제 （ｚａｋ）에 의해 매개된 장애의 치료를 위한 피리미딜아미노벤즈아미드 유도체의 용도
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
MX2012004709A (es) 2009-10-23 2012-05-23 Novartis Ag Metodo para el tratamiento de transtornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r.
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2010KO00035A (hr) * 2010-01-15 2016-09-02
EP2558098A2 (en) 2010-04-16 2013-02-20 Novartis AG Treatment of endocrine resistant breast cancer
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
PL2571863T3 (pl) 2010-06-21 2016-03-31 Teva Pharma Sole nilotynibu i ich postacie krystaliczne
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
IN2010CH03577A (hr) * 2010-11-26 2012-07-20 Hetero Research Foundation
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
CA2853095A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
CA2855503A1 (en) 2011-11-14 2013-05-23 Novartis Ag Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
EP2626355B1 (en) * 2012-02-09 2016-02-03 Natco Pharma Limited Process for the preparation of nilotinib hydrochloride
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
EP2872142A1 (en) 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
US9376419B2 (en) 2012-10-15 2016-06-28 Apotex Inc. Solid forms of nilotinib hydrochloride
EP2909191B1 (en) * 2012-10-19 2019-03-20 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
RU2619944C2 (ru) * 2013-02-21 2017-05-22 Пфайзер Инк. Твердые формы селективного ингибитора CDK4/6
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN105324375A (zh) * 2013-04-24 2016-02-10 雷迪博士实验室有限公司 盐酸尼洛替尼的多晶型形式
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
EP3177610A4 (en) 2014-08-08 2018-01-10 Dr. Reddy's Laboratories Ltd. Process for the preparation of polymorphic forms of nilotinib
MX2017004770A (es) * 2014-10-16 2017-07-26 Apotex Inc Formas solidas del clorhidrato de nilotinib.
WO2017129694A1 (en) 2016-01-26 2017-08-03 Farma Grs, D.O.O. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
WO2017160703A1 (en) 2016-03-14 2017-09-21 Pliva Hrvatska D.O.O. Solid state forms of nilotinib salts
CN106496193A (zh) * 2016-09-13 2017-03-15 福格森（武汉）生物科技股份有限公司 一种高纯度尼罗替尼的制备方法
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CN113321647B (zh) 2018-06-15 2024-08-27 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法
WO2020095187A1 (en) * 2018-11-05 2020-05-14 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
WO2021155254A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
WO2022068876A1 (en) 2020-09-29 2022-04-07 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
WO2022263510A1 (en) 2021-06-19 2022-12-22 Helm Ag Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
CN113788817A (zh) * 2021-09-27 2021-12-14 南京海润医药有限公司 一种尼罗替尼半盐酸盐一水合物晶型及其制备方法
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
CN116102540B (zh) * 2023-01-05 2025-03-25 浙江工业大学 两种尼洛替尼游离碱新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701406A (en) 1901-07-16 1902-06-03 Thomas K Jones Cut-off-valve mechanism.
US701405A (en) 1902-02-17 1902-06-03 Archibald White Maconochie Ejecting device for stamping-machines.
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
RU2362562C2 (ru) * 2003-11-18 2009-07-27 Новартис Аг Ингибиторы мутантной формы киназы kit
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Also Published As

Publication number Publication date
UA94234C2 (uk) 2011-04-26
KR20080027853A (ko) 2008-03-28
PL2284167T3 (pl) 2017-07-31
EP2284168A3 (en) 2011-04-13
US8415363B2 (en) 2013-04-09
GEP20115302B (en) 2011-10-10
MA29626B1 (fr) 2008-07-01
EA013464B1 (ru) 2010-04-30
US20140343087A1 (en) 2014-11-20
US20130165465A1 (en) 2013-06-27
CA2614334A1 (en) 2007-02-08
JP2013018789A (ja) 2013-01-31
HRP20170634T4 (hr) 2020-02-07
SG163620A1 (en) 2010-08-30
HK1116783A1 (en) 2009-01-02
NZ564409A (en) 2011-07-29
US20130023548A1 (en) 2013-01-24
BRPI0613615B1 (pt) 2022-02-08
CR9657A (es) 2008-04-16
ES2648288T3 (es) 2017-12-29
IL188189A0 (en) 2008-03-20
ECSP088119A (es) 2008-02-20
KR20130077915A (ko) 2013-07-09
DK2284167T4 (da) 2020-03-02
WO2007015870A3 (en) 2007-06-07
AU2012201453B2 (en) 2013-09-05
ES2386974T3 (es) 2012-09-10
HN2008000311A (es) 2011-01-24
EP2284167A2 (en) 2011-02-16
AR054846A1 (es) 2007-07-18
EP1912973A2 (en) 2008-04-23
EP2284167B1 (en) 2017-02-01
GT200600315A (es) 2007-03-19
AU2012201453C1 (en) 2024-05-23
CN103804356A (zh) 2014-05-21
AU2012201453A1 (en) 2012-04-05
JO3308B1 (ar) 2018-09-16
TWI406661B (zh) 2013-09-01
EA016856B1 (ru) 2012-08-30
CU20080006A7 (es) 2011-02-24
JP2014221831A (ja) 2014-11-27
EP2535337A1 (en) 2012-12-19
BRPI0613615A2 (pt) 2011-01-18
EP2535337B1 (en) 2017-08-23
JP2009502795A (ja) 2009-01-29
AU2006276204A1 (en) 2007-02-08
SI2284167T2 (sl) 2020-03-31
TW200740793A (en) 2007-11-01
CN102358736A (zh) 2012-02-22
CY1119624T1 (el) 2018-04-04
RS55929B1 (sr) 2017-09-29
KR20130085444A (ko) 2013-07-29
AU2011202047A1 (en) 2011-05-26
PH12013501590A1 (en) 2015-09-21
CU23916B1 (es) 2013-07-31
ES2623608T3 (es) 2017-07-11
MY148554A (en) 2013-04-30
HUE031791T2 (en) 2017-08-28
JP5798101B2 (ja) 2015-10-21
EP2284167B2 (en) 2019-11-27
CY1113076T1 (el) 2016-04-13
SI1912973T1 (sl) 2012-08-31
SMP200800011B (it) 2008-02-27
KR101651288B1 (ko) 2016-08-25
ES2623608T5 (es) 2020-06-18
DK2284167T3 (en) 2017-05-01
EA201000145A1 (ru) 2010-06-30
NI200800017A (es) 2009-03-03
NO341930B1 (no) 2018-02-19
DK1912973T3 (da) 2012-07-23
US8829015B2 (en) 2014-09-09
EP2284167A3 (en) 2011-03-02
IL214659A0 (en) 2011-09-27
CA2614334C (en) 2015-04-21
EP2284168A2 (en) 2011-02-16
PT2284167T (pt) 2017-05-15
JP5289948B2 (ja) 2013-09-11
PE20070214A1 (es) 2007-04-02
US20080269269A1 (en) 2008-10-30
HRP20120573T1 (hr) 2012-08-31
LT2284167T (lt) 2017-04-25
PT1912973E (pt) 2012-09-03
TNSN08029A1 (en) 2009-07-14
NO20080820L (no) 2008-04-15
PL1912973T3 (pl) 2012-09-28
MX2008000899A (es) 2008-03-18
US8343984B2 (en) 2013-01-01
EP1912973B1 (en) 2012-06-13
EA200800201A1 (ru) 2008-06-30
EP2543665A2 (en) 2013-01-09
SMAP200800011A (it) 2008-02-27
PL2284167T5 (pl) 2020-07-27
WO2007015870A2 (en) 2007-02-08
EP2543665A3 (en) 2013-05-29
SI2284167T1 (sl) 2017-05-31
RS55929B2 (sr) 2020-12-31

Similar Documents

Publication Publication Date Title
HRP20170634T1 (hr) Kristalni oblici od 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
IL187787A0 (en) Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP1957462A4 (en) NEW 2-AMINO-HETEROCYCLES USEFUL FOR THE TREATMENT OF ABETA-RELATED DISEASES
EP1954362A4 (en) REGULATED PLAYING AND PLAYING MULTIPLE PLAYING GAMES
IL184834A0 (en) Compositions and methods for the manufacture thereof
EP1726304A4 (en) COMPOSITION CONTAINING SOLIFENACIN
EP1849481A4 (en) COMPOSITION FOR TOPICAL APPLICATION
ZA200708527B (en) Use of fuel composition
ZA200710799B (en) Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
DK2392335T3 (en) Use of 24-norUDCA
ZA200704974B (en) Composition
ZA200711021B (en) Novel hydrophilising agents/HSP-substituent
ZA200710457B (en) Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoro-methyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP1927349A4 (en) COMPOSITION FOR EXTENDING LIFE AND METHOD FOR EXTENDING LIFE
GB0415129D0 (en) Care composition
TWI319745B (en) Mold capable of adjusting the concentricity
GB2424794B (en) Improvements in the use of pre-configuration
GB0516290D0 (en) The game of nudgery
GB0506135D0 (en) Controlling use of content
GB0503366D0 (en) Personal golf course
TWM291594U (en) Improved structure of transformer
GB0519275D0 (en) Manufacture of Ifenprodil
TWM291236U (en) Improved structure of bookrack
HU0401418D0 (en) Personal care composition made from fig - and walnut - leaf
GB0420760D0 (en) Iron of trimmerrr